首頁 > 市場調查報告書 > 醫療設備

生技設備生物標記

市場調查報告書

商品編碼

1666175

全球細胞表面標記檢測市場 - 2025 至 2033 年

Global Cell Surface Markers Detection Market - 2025-2033

出版日期: 2025年02月24日 | 出版商:

DataM Intelligence | 英文 159 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球細胞表面標誌檢測市場規模達 52 億美元，預計到 2033 年將達到 107 億美元，2025-2033 年預測期內的複合年成長率為 8.4%。

細胞表面標誌檢測是生物醫學研究和臨床診斷的關鍵過程，涉及識別細胞外膜上的特定蛋白質、糖蛋白或其他分子。這些標記作為細胞類型、狀態和功能的唯一標識符，使研究人員和臨床醫生能夠區分不同的細胞群，例如免疫細胞、癌細胞或幹細胞。這種檢測對於診斷疾病、分類細胞類型和指導治療決策至關重要，特別是在腫瘤學、免疫學和再生醫學等領域。

由於精準醫療需求的增加、慢性病發病率的上升和技術的進步，細胞表面標誌檢測市場預計將快速成長。市場擴張的動力來自於其在診斷、個人化治療和藥物發現的應用。流式細胞儀、質譜法和免疫組織化學等領先技術以及對早期疾病檢測的日益關注，使其成為醫療保健和生物技術行業的重要投資領域。

例如，2024 年 8 月，安捷倫科技推出了其產品組合的最新成員 NovoCyte Opteon 光譜流式細胞儀，該產品能夠同時分析 40 多個標記，NovoCyte Opteon 使研究人員能夠進行大面板流式細胞儀檢測並進行複雜的細胞分析研究。

市場動態：

促進因素與約束因素

個人化醫療的應用日益增多

個人化醫療中日益成長的應用極大地推動了細胞表面標記檢測市場的成長，並預計將在預測期內推動市場的發展。個人化醫療涉及根據特定生物標記（包括細胞表面標記）對患者進行分類，以確定最有效的治療方法。

例如，在癌症治療中，檢測乳癌患者中的 HER2 標記有助於識別那些可以從曲妥珠單抗等 HER2 標靶療法中受益的患者。同樣，PD-L1 等標記物可以指導免疫檢查點抑制劑在肺癌中的使用。這種分層確保患者接受最合適、最有效的治療，從而增加了對精確的細胞表面標誌檢測技術的需求。

此外，旨在與特定細胞表面標記物相互作用的標靶療法的興起是個人化醫療的基石。單株抗體、CAR-T細胞療法和小分子抑制劑的開發針對CD20、CD19和EGFR等標記物，提供更精準、毒性更小的治療選擇。

在白血病中，特別是急性淋巴細胞白血病 (ALL) 和慢性淋巴細胞白血病 (CLL)，檢測特定的細胞表面標誌對於監測微小殘留疾病 (MRD) 至關重要，MRD 是指治療後殘留的少量癌細胞，可能導致復發。 CD19、CD20 和 CD34 等標記用於識別 MRD，指導進一步的治療決策並改善患者預後。因此，個人化醫療的興起正在改變疾病的診斷、治療和管理方式，大大增加了對細胞表面標記檢測技術的需求。

類似地，在多發性硬化症中，CD52 標記物是阿崙單抗的標靶藥物，阿崙單抗是一種單株抗體，可選擇性地消耗導致病情進展的免疫細胞。這些標靶治療依賴細胞表面標誌的準確檢測，這對於選擇正確的患者和監測治療效果至關重要。

標靶標記物可用性有限

目標細胞表面標記的有限可用性限制了全球細胞表面標記檢測市場，從而限制了先進檢測技術的發展和應用。標靶標記對於精準診斷和個人化治療策略至關重要，但其有限的發現和驗證可能會影響檢測方法的有效性和範圍。

例如，儘管生物標記研究取得了重大進展，但經過充分驗證的細胞表面標記的數量仍然有限。例如，雖然 PD-L1 和 CD19 等標記已得到充分證實並廣泛應用於癌症免疫治療，但對於許多其他癌症或複雜疾病，經過驗證的標記物較少。缺乏針對各種情況的全面標記物面板限制了開發有針對性的檢測方法的能力，並阻礙了個人化醫療的進展。

此外，發現和驗證新的細胞表面標誌需要大量的研究和開發，這可能耗費大量時間和資源。識別新的標記需要大規模研究和臨床試驗來確定其相關性和可靠性。例如，發現罕見癌症或特定亞型疾病的新標記通常需要大量的研究投資和機構間的合作。

市場領導者和先驅者
- 新興先鋒和傑出參與者
- 擁有最大銷售品牌的成熟領導者
- 擁有成熟產品的市場領導者
CXO 觀點
最新進展與突破
案例研究/正在進行的研究
監管和報銷情況
- 北美洲
- 歐洲
- 亞太地區
- 拉丁美洲
- 中東和非洲
波特五力分析
供應鏈分析
專利分析
SWOT 分析
未滿足的需求和差距
市場進入和擴張的推薦策略
情境分析：最佳情況、基本情況和最壞情況預測
定價分析和價格動態
關鍵意見領袖

第 5 章：細胞表面標記檢測市場（依產品類型）

流式細胞儀
血液學分析儀
細胞成像系統
試劑和試劑盒
其他

第 6 章：細胞表面標記檢測市場（依應用）

疾病診斷與鑑定
研究與藥物發現
其他

第 7 章：細胞表面標記檢測市場，按區域市場分析和成長機會

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
南美洲
- 巴西
- 阿根廷
- 南美洲其他地區
亞太
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲

第 8 章：競爭格局與市場定位

競爭概況和主要市場參與者
市佔率分析與定位矩陣
策略夥伴關係、併購
產品組合和創新的關鍵發展
公司基準化分析

第9章：公司簡介

Becton, Dickinson, and Company

公司概況
產品組合和描述
財務概覽
主要進展
SWOT 分析

NIHON KOHDEN CORPORATION
Sysmex Corporation
Thermo Fisher Scientific Inc.
Nexcelom Bioscience LLC
Beckman Coulter, Inc.
Agilent Technologies Inc.
Bio-Rad Laboratories, Inc.
Cytek Biosciences Inc
Miltenyi Biotec

第 10 章：假設與研究方法

資料收集方法
數據三角測量
預測技術
數據驗證和確認

第 11 章：附錄

簡介目錄

Product Code: MD3902

The global cell surface markers detection market reached US$ 5.2 billion in 2024 and is expected to reach US$ 10.7 billion by 2033, growing at a CAGR of 8.4% during the forecast period 2025-2033.

Cell surface marker detection is a critical process in biomedical research and clinical diagnostics that involves identifying specific proteins, glycoproteins or other molecules on the outer membrane of cells. These markers serve as unique identifiers of cell types, states and functions, enabling researchers and clinicians to distinguish between different cell populations, such as immune cells, cancer cells or stem cells. This detection is vital for diagnosing diseases, classifying cell types and guiding therapeutic decisions, especially in fields like oncology, immunology and regenerative medicine.

The cell surface marker detection market is expected to grow rapidly due to increasing demand for precision medicine, rising incidences of chronic diseases and technological advancements. The market's expansion is driven by its applications in diagnostics, personalized therapy and drug discovery. Leading technologies like flow cytometry, mass spectrometry and immunohistochemistry, along with the growing focus on early disease detection, make this an essential area of investment in both the healthcare and biotechnology industries.

For instance, in August 2024, Agilent Technologies unveiled the latest addition to its portfolio, the NovoCyte Opteon Spectral Flow Cytometer which is capable of simultaneously analyzing over 40 markers, the NovoCyte Opteon enables researchers to conduct large-panel flow cytometry assays and undertake sophisticated cell analysis research.

Market Dynamics: Drivers & Restraints

Rising applications in personalized medicine

The rising applications in personalized medicine are significantly driving the growth of the cell surface markers detection market and are expected to drive the market over the forecast period. Personalized medicine involves categorizing patients based on specific biomarkers, including cell surface markers, to determine the most effective treatment.

For instance, in cancer treatment, the detection of HER2 markers in breast cancer patients helps identify those who would benefit from HER2-targeted therapies like trastuzumab. Similarly, markers like PD-L1 guide the use of immune checkpoint inhibitors in lung cancer. This stratification ensures that patients receive the most appropriate and potentially effective treatment, increasing the demand for accurate cell surface marker detection technologies.

Additionally, the rise in targeted therapies, which are designed to interact with specific cell surface markers, is a cornerstone of personalized medicine. Monoclonal antibodies, CAR-T cell therapies, and small molecule inhibitors are developed to target markers such as CD20, CD19 and EGFR, providing more precise and less toxic treatment options.

In leukemia, particularly acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL), the detection of specific cell surface markers is crucial for monitoring minimal residual disease (MRD), which refers to the small number of cancer cells that remain after treatment and may lead to relapse. Markers like CD19, CD20 and CD34 are used to identify MRD, guiding further treatment decisions and improving patient prognosis. Thus, rising personalized medicine is transforming how diseases are diagnosed, treated and managed, significantly boosting the demand for cell surface marker detection technologies.

Similarly, in multiple sclerosis, CD52 markers are targeted by alemtuzumab, a monoclonal antibody that selectively depletes immune cells contributing to disease progression. These targeted therapies rely on the accurate detection of cell surface markers, which is essential for selecting the right patients and monitoring therapeutic efficacy.

Limited availability of targeted markers

The limited availability of targeted cell surface markers significantly restrains the global cell surface markers detection market by constraining the development and application of advanced detection technologies. Targeted markers are crucial for precise diagnostics and personalized treatment strategies, but their limited discovery and validation can impact the effectiveness and scope of detection methods.

For instance, despite significant advancements in biomarker research, the number of well-validated cell surface markers remains limited. For instance, while markers like PD-L1 and CD19 are well-established and widely used in cancer immunotherapy, there are fewer validated markers for many other cancers or complex diseases. The lack of comprehensive marker panels for various conditions limits the ability to develop targeted detection methods and hinders progress in personalized medicine.

Additionally, discovering and validating new cell surface markers involves extensive research and development, which can be time-consuming and resource-intensive. Identifying novel markers requires large-scale studies and clinical trials to establish their relevance and reliability. For instance, discovering new markers for rare cancers or specific subtypes of diseases often requires significant investment in research and collaboration between institutions.

Segment Analysis

The global cell surface markers detection market is segmented based on product type, application and region.

Product Type:

The flow cytometers segment is expected to dominate the cell surface markers detection market share

Flow cytometers are a laser-based technology used for cell counting, biomarker detection, cell sorting and protein engineering. It helps identify, characterize and isolate stem and progenitor cells for research and clinical use. The growing adoption of flow cytometry in stem cell research and its increasing applications in clinical research are expected to drive the segment's growth.

Flow cytometers aid in the identification, characterization and isolation of stem and progenitor cells for research and clinical use. It simplifies disease analysis, sample separation and diagnosis, and its increasing applications in clinical research are expected to drive market growth. For instance, in May 2024, Agilent Technologies Inc. unveiled the NovoCyte Opteon Spectral Flow Cytometer, offering configurations ranging from three to five lasers and supporting up to 73 high-quality detectors.

The analysis of cell-surface proteins by flow cytometry produces robust and quantitative information with single-cell resolution and allows live target cells to be purified and characterized or re-cultured. Various studies using antibody screens, proteomics and candidate analysis have identified a comprehensive set of proteins that are expressed on the surface of primed human pluripotent stem cells. For instance, in June 2024, Lund University's Biomedical Centre added a high-tech spectral flow cytometry instrument to its FACS Core Facility, enhancing speed and precision in cell research.

Geographical Analysis

North America is expected to hold a significant position in the cell surface markers detection market share

North America especially the United States leads global efforts in cancer research, with government initiatives such as the "Cancer Moonshot" driving research into immunotherapy, personalized medicine and biomarker detection. Cell surface markers are vital in this field, particularly for identifying specific populations of cancer cells and immune cells (like T cells) for diagnostics, prognostics and therapies. Companies like Thermo Fisher Scientific, Bio-Rad Laboratories and BD Biosciences are headquartered in the United States, dominating the market with cutting-edge technologies for cell marker detection.

For instance, on March 26, 2024, Bio-Rad Laboratories, Inc., launched validated antibodies for rare and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad's Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumor heterogeneity and disease progression at various stages. Bio-Rad's Genesis Cell Isolation System captures a wide range of CTCs and other rare cells from liquid biopsy samples. After capture, the cells can be recovered for downstream analysis or immunostained on-slide for immunofluorescence applications such as enumeration and identification of various CTC types.

In North America, the rising prevalence of cancer and chronic diseases has led to increased investment in cell surface marker detection. These markers are crucial for early diagnosis, patient stratification and monitoring treatment responses.

For instance, according to the National Institute of Health (NIH), in 2024, roughly 2.0 million people will be diagnosed with cancer in the United States. An estimated 310,720 women and 2,790 men will be diagnosed with breast cancer. Prostate cancer is the leading cancer diagnosis among men and the second most common diagnosis overall with 299,010 expected cases. Lung and bronchus cancer is the third most common cancer diagnosis with an estimated 234,580 new cases.

Additionally, in 2024, an estimated 611,720 people will die of cancer in the United States. Lung and bronchus cancer is responsible for the most deaths with 125,070 people expected to die from this disease. That is nearly three times the 53,010 deaths due to colorectal cancer, which is the second most common cause of cancer death. Pancreatic cancer is the third deadliest cancer, causing 51,750 deaths. This increasing prevalence of cancers and various chronic diseases may increase the demand for the cell surface marker detection market.

North America, particularly the United States has a strong presence of leading biotechnology and life sciences companies, including Bio-Rad Laboratories, Beckman Coulter and Thermo Fisher Scientific, which are continuously launching new products for cell surface marker detection. These advancements often center around flow cytometry and imaging technologies, both crucial for high-throughput and accurate cell marker identification.

For instance, in March 2024, Beckman Coulter Life Sciences received 510(k) clearance from the Food and Drug Administration (FDA) to distribute its DxFLEX Clinical Flow Cytometer in the United States. Launched regionally in 2020, this advancement brings the popular benchtop IVD flow cytometry system to American labs while expanding testing capabilities. Offering up to 13 colors, additional detectors can be activated as laboratory needs evolve without the need to purchase additional hardware.

Asia-Pacific is growing at the fastest pace in the Cell Surface Markers Detection market

The demand for cell surface markers detection in the Asia-Pacific region, including major countries like China, India, Japan, South Korea and others, is experiencing rapid growth. This growth is driven by the increasing prevalence of chronic diseases such as cancer, autoimmune disorders and infectious diseases, coupled with rising investments in biotechnology and healthcare infrastructure. The Asia-Pacific region is emerging as a key region in the global cell surface marker detection market, with the expansion of research and development activities, growing adoption of advanced diagnostics and government initiatives aimed at improving healthcare.

China has one of the highest cancer rates, particularly for lung, breast and gastrointestinal cancers. This has led to a significant increase in demand for early detection technologies, including cell surface marker detection, which is critical for diagnostics and treatment monitoring. China's government has made substantial investments in cancer research, with institutions like the National Cancer Center of China playing a pivotal role in advancing cancer immunotherapy and personalized medicine.

For instance, according to the National Institute of Health, lung cancer is the most common cancer in China in 2022 (1,060,600 cases), followed by colorectal cancer (517,100 cases), thyroid cancer (466,100 cases), liver cancer (367,700 cases) and stomach cancer (358,700 cases), accounting for 57.42% of total new cancer cases. This is suspected to boost the market in the region.

India is witnessing a rise in cancer cases, particularly breast and cervical cancer. Additionally, the country faces a high burden of infectious diseases like tuberculosis and HIV. The detection of cell surface markers is essential in both oncology and infectious disease diagnostics. The Indian government, along with private healthcare companies like Dr. Reddy's Laboratories and Biocon, is increasingly focusing on cancer research and diagnostic improvements, which is driving the demand for advanced detection technologies.

For instance, according to the National Institute of Health, in India, the incidence of cancer cases is likely to increase from 1.46 million in 2022 to 1.57 million in 2025. Lung cancer was estimated to be 1,03,371 cases in 2022 and it featured in the top five leading sites for both males and females. The estimates for cancer in India increased by five percent (14,61,427 in 2022 compared to 13,92,179 in 2020). This directly boosts the demand for cell surface markers detection market in India.

China is rapidly advancing its capabilities in precision oncology. With the government's "Healthy China 2030" plan prioritizing cancer care and innovative treatments, cell surface marker detection has become integral to research and clinical trials. Companies are at the forefront of developing targeted therapies that depend on accurate detection of markers such as PD-L1 and CD20.

Competitive Landscape

The major global players in the cell surface markers detection market include Becton, Dickinson, and Company, NIHON KOHDEN CORPORATION, Sysmex Corporation, Thermo Fisher Scientific Inc., Nexcelom Bioscience LLC, Beckman Coulter, Inc., Agilent Technologies Inc., Bio-Rad Laboratories, Inc., Cytek Biosciences Inc, Miltenyi Biotec and among others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global cell surface markers detection market report delivers a detailed analysis with 54 key tables, more than 44 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Market Introduction and Scope

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. Executive Insights and Key Takeaways

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Application
2.5. Snippet by Region

3. Dynamics

3.1. Impacting Factors
- 3.1.1. Drivers
  - 3.1.1.1. Rising Applications in Personalized Medicine
- 3.1.2. Restraints
  - 3.1.2.1. Limited Availability of Targeted Markers
- 3.1.3. Opportunity
- 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

4.1. Market Leaders and Pioneers
- 4.1.1. Emerging Pioneers and Prominent Players
- 4.1.2. Established leaders with largest selling Brand
- 4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. Regulatory and Reimbursement Landscape
- 4.5.1. North America
- 4.5.2. Europe
- 4.5.3. Asia Pacific
- 4.5.4. Latin America
- 4.5.5. Middle East & Africa
4.6. Porter's Five Force Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders

5. Cell Surface Markers Detection Market, By Product Type

5.1. Introduction
- 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 5.1.2. Market Attractiveness Index, By Product Type
5.2. Flow Cytometry*
- 5.2.1. Introduction
- 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Hematology Analyzers
5.4. Cell Imaging Systems
5.5. Reagents and Kits
5.6. Others

6. Cell Surface Markers Detection Market, By Application

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 6.1.2. Market Attractiveness Index, By Application
6.2. Disease Diagnosis and Identification*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Research & Drug Discovery
6.4. Others

7. Cell Surface Markers Detection Market, By Regional Market Analysis and Growth Opportunities

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 7.1.2. Market Attractiveness Index, By Region
7.2. North America
- 7.2.1. Introduction
- 7.2.2. Key Region-Specific Dynamics
- 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 7.2.5.1. U.S.
  - 7.2.5.2. Canada
  - 7.2.5.3. Mexico
7.3. Europe
- 7.3.1. Introduction
- 7.3.2. Key Region-Specific Dynamics
- 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 7.3.5.1. Germany
  - 7.3.5.2. U.K.
  - 7.3.5.3. France
  - 7.3.5.4. Spain
  - 7.3.5.5. Italy
  - 7.3.5.6. Rest of Europe
7.4. South America
- 7.4.1. Introduction
- 7.4.2. Key Region-Specific Dynamics
- 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 7.4.5.1. Brazil
  - 7.4.5.2. Argentina
  - 7.4.5.3. Rest of South America
7.5. Asia-Pacific
- 7.5.1. Introduction
- 7.5.2. Key Region-Specific Dynamics
- 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 7.5.5.1. China
  - 7.5.5.2. India
  - 7.5.5.3. Japan
  - 7.5.5.4. South Korea
  - 7.5.5.5. Rest of Asia-Pacific
7.6. Middle East and Africa
- 7.6.1. Introduction
- 7.6.2. Key Region-Specific Dynamics
- 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

8. Competitive Landscape and Market Positioning

8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking

9. Company Profiles

9.1. Becton, Dickinson, and Company*
- 9.1.1. Company Overview
- 9.1.2. Product Portfolio and Description
- 9.1.3. Financial Overview
- 9.1.4. Key Developments
- 9.1.5. SWOT Analysis
9.2. NIHON KOHDEN CORPORATION
9.3. Sysmex Corporation
9.4. Thermo Fisher Scientific Inc.
9.5. Nexcelom Bioscience LLC
9.6. Beckman Coulter, Inc.
9.7. Agilent Technologies Inc.
9.8. Bio-Rad Laboratories, Inc.
9.9. Cytek Biosciences Inc
9.10. Miltenyi Biotec